View Post

Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

In Clinical Studies News by Barbara Jacoby

Source: Inbiomotion From: prnewswire.com – Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis – Data published in Journal of National Cancer Institute, Cancer Spectrum – MAF-negative status of patients who were …

View Post

Ines Vaz-Luis, MD, PhD, on Risk Assessment in Premenopausal Hormone Receptor-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jeff Minerd From: medpagetoday.com Online calculators, composite scores, and genetic assays can all inform treatment decisions Premenopausal women with hormone receptor-positive, early-stage breast cancer often present with more complex disease. They tend to require multimodality therapy and have inferior survival outcomes compared with postmenopausal women, noted Ines Vaz-Luis, MD, PhD, of Institut Gustave Roussy in Villejuif, France, and co-authors, …

View Post

City of Hope researchers ID how most common breast cancer becomes resistant to treatment

In Clinical Studies News by Barbara Jacoby

Source: City of Hope From: eurekalert.org Understanding how tumors in patients with early-stage estrogen receptor positive breast cancer evolve to resist certain combination therapies can aid in the design of optimal drug strategies for people whose cancer potentially could be cured City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage …

View Post

Rapid Update to ASCO Breast Cancer Guidelines After OlympiA Data

In Clinical Studies News by Barbara Jacoby

By: Sharon Worcester From: medscape.com The American Society of Clinical Oncology (ASCO) now recommends offering 1 year of adjuvant olaparib therapy to patients with early-stage HER2-negative, BRCA-mutated breast cancer who have completed chemotherapy and local treatment. The change in management of hereditary breast cancer is outlined in an update to 2020 guidelines, and it comes as a “rapid recommendation” on …

View Post

Pinpoint Patient Recruiting: Help Us Better Understand the Early Breast Cancer Journey

In Paid Opportunities For The Cancer Community by Barbara Jacoby

What is the Study? The purpose of this study is to get a deeper understanding of the patient experience along the early breast cancer journey. Participants will be asked to do the following: Participate in an online community over a 2 week period (only a few minutes a day) Complete a 60 min interview Who Qualifies? Patients and/or their caregivers …

View Post

New technology benefiting breast cancer patients

In In The News by Barbara Jacoby

Source: THOMPSON HEALTH From: mpnnow.com The Breast Imaging Center and Breast Surgery Program at UR Medicine Thompson Health are among the first in the region to offer Savi Scout radar localization technology to treat women diagnosed with early-stage breast cancer. The technology makes lumpectomies easier for patients and their surgeons by pinpointing tumors before surgery. Surgeons are able to go …

View Post

Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics

In Clinical Studies News by Barbara Jacoby

Source: Newsfile Corp. From: finance.yahoo.com – The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment – Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) (“Portage” or the “Company”) a clinical stage immuno-oncology company accelerating research and …

View Post

Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: onclive.com Investigators are seeking to determine whether amcenestrant (SAR439859), an investigational oral endocrine therapy, can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer. The phase 2 AMEERA-4 trial (NCT04191382) is testing 2 dose levels of amcenestrant versus letrozole given for 14 days to patients with …

View Post

Trial results extend add to uses for Exact Sciences test

In Clinical Studies News by Barbara Jacoby

By: Joel Berg From: medcitynews.com The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy — and those who won’t. The latest trial results extend the test’s reach. A clinical trial shows that a genomic test from diagnostics company Exact Sciences can help more women with early-stage breast …

View Post

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS

In In The News by Barbara Jacoby

From: businesswire.com Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. …